Clinical Trial Update: Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pyrotinib in combination with letrozole for HER2-positive, ER-positive metastatic breast cancer; status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Letrozole (letrozole)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN